BSX
NYSE · Health Care
Boston Scientific Corp
$42.75
-1.89 (-4.23%)
Financial Highlights (FY 2026)
Revenue
19.63B
Net Income
2.83B
Gross Margin
69.0%
Profit Margin
14.4%
Rev Growth
+16.5%
D/E Ratio
0.47
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 69.0% | 69.0% | 48.4% | 48.4% |
| Operating Margin | 18.0% | 16.2% | 9.6% | 7.6% |
| Profit Margin | 14.4% | 13.7% | 6.7% | 6.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 19.63B | 16.84B | 92.67B | 78.46B |
| Gross Profit | 13.55B | 11.62B | 44.84B | 37.96B |
| Operating Income | 3.53B | 2.73B | 8.94B | 5.97B |
| Net Income | 2.83B | 2.19B | 6.21B | 4.86B |
| Gross Margin | 69.0% | 69.0% | 48.4% | 48.4% |
| Operating Margin | 18.0% | 16.2% | 9.6% | 7.6% |
| Profit Margin | 14.4% | 13.7% | 6.7% | 6.2% |
| Rev Growth | +16.5% | +16.5% | +24.5% | -0.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 10.02B | 10.02B | 41.85B | 48.83B |
| Total Equity | 21.22B | 21.22B | 39.78B | 34.13B |
| D/E Ratio | 0.47 | 0.47 | 1.05 | 1.43 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 4.41B | 3.60B | 11.32B | 10.30B |
| Free Cash Flow | — | — | 4.47B | 5.22B |